Prospect of new drug research and development: the era of heavy bomb will continue

Many well-known analysts in the pharmaceutical industry have assessed the current status of drug development, indicating that the dawn of new drug research and development has emerged Human genomics plays a key role in the development of chemical and biological drugs The demand of patients for new drug efficacy makes it more urgent to improve the productivity of new drug research and development and update the new drug development model In the new year, biological products have become the focus area of new drug development Drug development is catching up with the pace of genomics revolution Many new drugs with great commercial potential are enough to make us conclude that it is too early to predict the end of the era of selling "blockbuster" products with more than one billion dollars In this paper, we will forecast and prospect the drug research and development in various disease fields in this year and in the future, so as to observe the trend and trend of new drug research and development in the "next generation" Hepatitis C drugs: competition is still fierce With the increasing demand of patients for safer and more convenient drugs, the development of hepatitis C drugs has not been reduced, and its future business prospects are considerable Although at the forty-seventh European Association for liver research (EASL) International Liver Disease Conference held in April 2012, nucleotide analogue polymerase inhibitor (NUC) took the lead, then in August 2012, Bristol Myers Squibb /Inhibitex 's NUC compound BMS-986094 was terminated due to cardiovascular adverse reactions, and Idenix' s late NUC drug IDX719 was also due to safety issues I have to apply to the FDA again Today, only the sofosbuvir (gs-7977) of Gilead science company is in phase III clinical trial If approved, evaluatepharma, a consultancy, predicts sales of the drug will reach $5.8 billion in 2018 Simeprevir, a protease inhibitor jointly developed by Bristol Myers Squibb / Johnson / mepir, is currently undergoing a controlled study of a compound drug composed of daclatasvir, an NS5A inhibitor of Bristol Myers Squibb If there is no accident, the drug may be approved for marketing in 2014 Abbott's abt-450, an oral ns34a inhibitor, and Abbott's galibavelin are in phase III clinical trials, with the goal of being approved for marketing in 2015 At the annual meeting of the American Association for the study of liver diseases (AASLD) held in Boston in November 2012, Abbott said that its abt-450 had achieved good results in phase II B clinical trials ADIS R & D insight predicted that by 2019, abt-450 would achieve "blockbuster" sales volume Roche will continue to focus on non NUCs, such as setrobuvir, danoprevir, mericitabine and compound preparations (currently in phase II clinical trials) At present, sovaprevir, a protease inhibitor from Achillion pharmaceutical company, has also entered the phase II clinical trial Rheumatoid arthritis drugs: JAK3 inhibitors dominate Although Pfizer's JAK3 inhibitor, tofacitinib, has some safety problems, it was finally approved in November 2012 Michael Ravi, an analyst at decision resources, believes that factitinib is the first approved DMARDs in the past 10 years, and its annual sales are expected to reach US $1.2 billion in 2018, while ADIS R & D insight predicts that it will reach the "blockbuster" status by 2015 Although Abbott's adamutumab patent is still early to expire, the company has made the development of oral JAK inhibitors as the focus of its future rheumatoid arthritis drug research In February 2012, Abbott signed a transaction agreement with Galapagos company of Belgium and obtained the oral Jak1 inhibitor GlpG 0634 (currently in phase II clinical trial) GlpG 0634 has achieved good results in clinical trials in Eastern Europe The industry expects GlpG 0634 to be approved by January 2017 Barictinib, developed jointly by Incyte and Lilly, is also an oral JAK inhibitor and has entered the phase II clinical trial Oral JAK inhibitors are not the only choice for the development of new rheumatoid arthritis drugs Rigel pharmaceutical and AstraZeneca have another way to develop fostamatinib, an oral Syk kinase inhibitor (currently in phase III clinical stage) Michael Ravi predicts fosamatinib will be approved for listing in 2015 and will reach $450 million in sales by 2018 Cancer drugs: many achievements are expected In the field of cancer medicine, no matter the traditional leader or the rising star, the recent success depends on improving the safety and effectiveness of the product In the field of malignant melanoma, zelboraf is a kind of BRAF inhibitor It works faster and has a good response rate, but only about half of the patients have BRAF mutation Roche recently announced the launch of phase III clinical trial of zelboraf / gdc-0973 compound, a small MEK inhibitor obtained from exelixis's kinase inhibitor development platform GlaxoSmithKline is also developing a malignant melanoma drug, BRAF inhibitor dabrafenib, similar to zelboraf, which is developed at the same time with the diagnostic products of bio Merieux SA in France A new oral targeting drug of GlaxoSmithKline, dabrafenib, and a combination of GlaxoSmithKline and trametinib, a MEK inhibitor of Japan Tobacco Company, are also under development Dabrafenib and trametinib are pre registered as single therapeutic drugs in the United States and Europe respectively GlaxoSmithKline is conducting phase III clinical trials of its compound preparations Two phase III clinical studies published at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) show that dabrafenib and trametinib are superior to chemotherapy drugs in the treatment of BRAF mutant melanoma.